JP2023531990A5 - - Google Patents
Info
- Publication number
- JP2023531990A5 JP2023531990A5 JP2022579797A JP2022579797A JP2023531990A5 JP 2023531990 A5 JP2023531990 A5 JP 2023531990A5 JP 2022579797 A JP2022579797 A JP 2022579797A JP 2022579797 A JP2022579797 A JP 2022579797A JP 2023531990 A5 JP2023531990 A5 JP 2023531990A5
- Authority
- JP
- Japan
- Prior art keywords
- nonspecific binding
- binding
- transfectant
- pseudo
- observed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062705434P | 2020-06-26 | 2020-06-26 | |
| US62/705,434 | 2020-06-26 | ||
| US202062705608P | 2020-07-07 | 2020-07-07 | |
| US62/705,608 | 2020-07-07 | ||
| EP20205426.8 | 2020-11-03 | ||
| EP20205426 | 2020-11-03 | ||
| PCT/EP2021/067574 WO2021260206A2 (en) | 2020-06-26 | 2021-06-25 | Chemokine receptor antibodies binding sulfated trd motifs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023531990A JP2023531990A (ja) | 2023-07-26 |
| JP2023531990A5 true JP2023531990A5 (https=) | 2024-07-02 |
Family
ID=76553783
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022579794A Pending JP2023531988A (ja) | 2020-06-26 | 2021-06-25 | 治療用途のためのｃｃｒ８抗体 |
| JP2022579797A Pending JP2023531990A (ja) | 2020-06-26 | 2021-06-25 | 硫酸化ｔｒｄモチーフに結合するケモカイン受容体抗体 |
| JP2022579796A Pending JP2023531989A (ja) | 2020-06-26 | 2021-06-25 | Ｃｃｒ８抗体及びその使用 |
| JP2022579795A Pending JP2023531705A (ja) | 2020-06-26 | 2021-06-25 | 抗ｃｃｒ８抗体療法：バイオマーカー及び併用療法 |
| JP2022579798A Pending JP2023531991A (ja) | 2020-06-26 | 2021-06-25 | ケモカイン受容体抗体生成のための硫酸化ペプチド |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022579794A Pending JP2023531988A (ja) | 2020-06-26 | 2021-06-25 | 治療用途のためのｃｃｒ８抗体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022579796A Pending JP2023531989A (ja) | 2020-06-26 | 2021-06-25 | Ｃｃｒ８抗体及びその使用 |
| JP2022579795A Pending JP2023531705A (ja) | 2020-06-26 | 2021-06-25 | 抗ｃｃｒ８抗体療法：バイオマーカー及び併用療法 |
| JP2022579798A Pending JP2023531991A (ja) | 2020-06-26 | 2021-06-25 | ケモカイン受容体抗体生成のための硫酸化ペプチド |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US20230250178A1 (https=) |
| EP (5) | EP4171602A2 (https=) |
| JP (5) | JP2023531988A (https=) |
| KR (2) | KR20230028780A (https=) |
| CN (6) | CN117653725A (https=) |
| AU (2) | AU2021212327A1 (https=) |
| BR (1) | BR112022026121A2 (https=) |
| CA (3) | CA3188142A1 (https=) |
| CL (1) | CL2022003747A1 (https=) |
| IL (2) | IL298896A (https=) |
| JO (1) | JOP20220352A1 (https=) |
| MX (2) | MX2022015954A (https=) |
| PE (1) | PE20231200A1 (https=) |
| TW (1) | TW202216771A (https=) |
| WO (5) | WO2021152186A2 (https=) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI890283B (zh) | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| AU2021244200A1 (en) * | 2020-03-23 | 2022-11-24 | Bristol-Myers Squibb Company | Anti-CCR8 antibodies for treating cancer |
| WO2022004760A1 (ja) * | 2020-06-30 | 2022-01-06 | 塩野義製薬株式会社 | 抗ｃｃｒ８抗体と化学療法剤の併用 |
| EP4010378B1 (en) | 2020-10-16 | 2026-05-06 | LaNova Medicines Limited | Anti-ccr8 monoclonal antibodies and uses thereof |
| CN117295820A (zh) | 2021-03-31 | 2023-12-26 | 盐野义制药株式会社 | 以ccr8作为抗原识别的嵌合抗原受体 |
| JP2024522360A (ja) | 2021-06-04 | 2024-06-18 | アムジエン・インコーポレーテツド | 抗ｃｃｒ８抗体及びその使用 |
| FI4214240T3 (fi) | 2021-07-27 | 2024-11-14 | Abbvie Inc | Ccr8-vasta-aineita |
| KR20240046533A (ko) * | 2021-08-20 | 2024-04-09 | 하이파이바이오 인코퍼레이티드 | 항-ccr8 항체 및 그것의 용도 |
| AU2022375782B2 (en) | 2021-10-28 | 2026-02-26 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| JP7787991B2 (ja) | 2021-10-29 | 2025-12-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
| CN116023468A (zh) * | 2021-11-05 | 2023-04-28 | 山东省分析测试中心 | 一种ccr6单克隆抗体及其在免疫及抗肿瘤中的应用 |
| US20250034266A1 (en) * | 2021-12-02 | 2025-01-30 | Zai Lab (Shanghai) Co., Ltd. | Ccr8 antigen binding unit and uses thereof |
| KR20240123836A (ko) | 2021-12-22 | 2024-08-14 | 길리애드 사이언시즈, 인코포레이티드 | 이카로스 아연 핑거 패밀리 분해제 및 이의 용도 |
| US12122764B2 (en) | 2021-12-22 | 2024-10-22 | Gilead Sciences, Inc. | IKAROS zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CR20240451A (es) | 2022-04-21 | 2024-12-04 | Gilead Sciences Inc | Compuestos de modulación de kras g12d |
| EP4532547A1 (en) | 2022-05-24 | 2025-04-09 | Bristol-Myers Squibb Company | Antibodies that bind to human ccr8 |
| CA3258344A1 (en) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals, Inc. | CHELETARIANS AND BIFUNCTIONAL CONJUGATES |
| AU2023290273A1 (en) * | 2022-06-14 | 2024-12-12 | Purdue Research Foundation | Car-expressing pluripotent stem cell-derived neutrophils loaded with drug nanoparticles and uses thereof |
| KR20250028371A (ko) | 2022-07-01 | 2025-02-28 | 길리애드 사이언시즈, 인코포레이티드 | Cd73 화합물 |
| WO2024026400A2 (en) * | 2022-07-27 | 2024-02-01 | Varian Medical Systems, Inc. | Therapeutic combinations of titr effectors with radiation therapy |
| CN119894532A (zh) * | 2022-09-09 | 2025-04-25 | 拜耳公司 | Ccr8抗体的医学用途和给药计划 |
| WO2024062076A1 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| CN120380018A (zh) * | 2022-09-21 | 2025-07-25 | 莫纳什大学 | 抗ccr8抗体 |
| WO2024062072A2 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| EP4590705A1 (en) | 2022-09-21 | 2025-07-30 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2024077239A1 (en) * | 2022-10-07 | 2024-04-11 | Genentech, Inc. | Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies |
| AU2023370501A1 (en) * | 2022-10-28 | 2025-05-01 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Anti-ccr8 antibodies and uses thereof |
| JP2025537137A (ja) * | 2022-11-04 | 2025-11-14 | ギリアード サイエンシーズ， インコーポレイテッド | 抗ｃｃｒ８抗体、化学療法及び免疫療法の組み合わせを使用する抗がん療法 |
| KR20250130296A (ko) * | 2022-11-22 | 2025-09-01 | 상하이 홍쳉 바이오파머수티컬 코., 엘티디. | 항-ccr8 항체 및 이의 용도 |
| AU2023409398A1 (en) | 2022-12-22 | 2025-06-05 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| EP4661869A1 (en) * | 2023-02-06 | 2025-12-17 | Bayer Aktiengesellschaft | Combinations of dgk (diacylglycerol kinase) inhibitors and immune checkpoint inhibitors and modulators |
| AU2024252725A1 (en) | 2023-04-11 | 2025-11-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| CR20250446A (es) | 2023-04-21 | 2025-12-02 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| WO2024240224A1 (zh) * | 2023-05-23 | 2024-11-28 | 再鼎医药(上海)有限公司 | 包含抗ccr8抗体的制剂及其用途 |
| JPWO2024248037A1 (https=) | 2023-05-30 | 2024-12-05 | ||
| EP4727974A1 (en) * | 2023-06-16 | 2026-04-22 | Genor Biopharma Co., Ltd. | Anti-ccr8 antibody and anti-ccr8/ctla4 bispecific antibody |
| AU2024306338A1 (en) | 2023-06-30 | 2026-01-08 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2025011439A1 (zh) * | 2023-07-07 | 2025-01-16 | 齐鲁制药有限公司 | 一种抗人ccr8的单克隆抗体药物制剂及其用途 |
| KR20260046403A (ko) | 2023-07-26 | 2026-04-07 | 길리애드 사이언시즈, 인코포레이티드 | Parp7 저해제 |
| CN121620513A (zh) | 2023-07-26 | 2026-03-06 | 吉利德科学公司 | Parp7抑制剂 |
| CN117285627B (zh) * | 2023-09-06 | 2024-06-14 | 百济神州(上海)生物科技有限公司 | 抗ccr8抗体及其用途 |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| CN121793988A (zh) | 2023-09-13 | 2026-04-03 | 东丽株式会社 | 癌的治疗、预防和/或诊断用药物组合物 |
| EP4590714A1 (en) | 2023-09-21 | 2025-07-30 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| EP4590715A1 (en) | 2023-09-21 | 2025-07-30 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| TW202529804A (zh) | 2023-10-06 | 2025-08-01 | 美商安進公司 | 用於癌症治療的組合療法 |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| TW202540200A (zh) | 2023-12-01 | 2025-10-16 | 美商基利科學股份有限公司 | 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2025146065A1 (en) * | 2024-01-05 | 2025-07-10 | LaNova Medicines Limited | Clinical regimens of anti-ccr8 antibodies |
| WO2025186043A1 (en) | 2024-03-06 | 2025-09-12 | Bayer Aktiengesellschaft | Pharmaceutical formulation for anti-ccr8 antibodies |
| CN118608914B (zh) * | 2024-04-25 | 2024-11-29 | 中山大学附属第一医院 | 一种病理图像上三级淋巴结构的识别方法、装置、计算机设备及可读存储介质 |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025259871A1 (en) | 2024-06-14 | 2025-12-18 | Gilead Sciences, Inc. | Anti-ccr8 antibodies and uses thereof |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| US20260098049A1 (en) | 2024-08-12 | 2026-04-09 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| US6329510B1 (en) | 1999-01-29 | 2001-12-11 | Millennium Pharmaceuticals, Inc. | Anti-CCR1 antibodies and methods of use therefor |
| AU2001250412A1 (en) * | 2000-03-31 | 2001-10-08 | Ipf Pharmaceuticals Gmbh | Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using specific chemokine receptor analysis and the chemokine receptor-ligand interaction |
| WO2003096020A2 (en) | 2002-05-13 | 2003-11-20 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with chemokine receptor 8 (ccr8) |
| US20080260744A1 (en) * | 2002-09-09 | 2008-10-23 | Omeros Corporation | G protein coupled receptors and uses thereof |
| EP1581648A2 (en) * | 2002-09-09 | 2005-10-05 | Nura, Inc. | G protein coupled receptors and uses thereof |
| US20050069955A1 (en) | 2003-06-30 | 2005-03-31 | Daniel Plaksin | Antibodies and uses thereof |
| BRPI0411945A (pt) * | 2003-06-30 | 2006-10-24 | Bio Technology General Israel | Anticorpos e seus usos |
| US20050266009A1 (en) | 2003-06-30 | 2005-12-01 | Savient Pharmaceuticals, Inc. | Antibodies and uses thereof |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| AU2005277831B2 (en) | 2004-07-10 | 2012-11-22 | The Institute For Cancer Research | Genetically modified human natural killer cell lines |
| WO2007044756A2 (en) | 2005-10-11 | 2007-04-19 | Icos Corporation | Monoclonal antibodies recognizing human ccr8 |
| US20070298034A9 (en) * | 2005-12-09 | 2007-12-27 | Angela Widom | Sulfotyrosine specific antibodies and uses therefor |
| CN101720368A (zh) | 2007-03-09 | 2010-06-02 | 中国抗体制药有限公司 | 储备多样性最大化的功能性人化抗体文库之构建及应用 |
| GB0904214D0 (en) * | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
| AR076284A1 (es) | 2009-04-29 | 2011-06-01 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| EP2480671B8 (en) | 2009-09-22 | 2015-10-28 | ProBioGen AG | Process for producing molecules containing specialized glycan structures |
| WO2015148820A1 (en) * | 2014-03-27 | 2015-10-01 | Massachusetts Institute Of Technology | Water-soluble membrane proteins and methods for the preparation and use thereof |
| US10087259B1 (en) * | 2014-04-28 | 2018-10-02 | Memorial Sloan Kettering Cancer Center | Depleting tumor-specific tregs |
| JP7093612B2 (ja) * | 2014-05-27 | 2022-06-30 | アカデミア シニカ | Ｂａｃｔｅｒｏｉｄｅｓ由来のフコシダーゼおよびそれを使用する方法 |
| MA41176A (fr) | 2014-12-17 | 2017-10-24 | Bayer As | Complexes radio-pharmaceutiques |
| DK3334457T3 (da) * | 2015-08-10 | 2020-09-21 | Pepmab B V | Humaniserede anti-CCR7-receptorantistoffer |
| CR20180243A (es) | 2015-10-02 | 2018-07-31 | Genentech Inc | Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso |
| EP4092045A1 (en) | 2016-05-16 | 2022-11-23 | Checkmab S.R.L. | Markers selectively deregulated in tumor-infiltrating regulatory t cells |
| WO2017218970A1 (en) | 2016-06-17 | 2017-12-21 | Varian Medical Systems, Inc. | Immune modulators in combination with radiation treatment |
| WO2018112032A1 (en) | 2016-12-13 | 2018-06-21 | President And Fellows Of Harvard College | Methods and compositions for targeting tumor-infiltrating tregs using inhibitors of ccr8 and tnfrsf8 |
| ES2863412T3 (es) | 2017-03-29 | 2021-10-11 | Shionogi & Co | Composición farmacéutica para el tratamiento del cáncer |
| CN111615520A (zh) * | 2017-12-01 | 2020-09-01 | 辉瑞大药厂 | 抗cxcr5抗体及其组合物和用途 |
| EP3746079A1 (en) | 2018-01-31 | 2020-12-09 | Bayer Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| WO2019157098A1 (en) * | 2018-02-06 | 2019-08-15 | Advaxis, Inc. | Compositions comprising a recombinant listeria strain and an anti-ccr8 antibody and methods of use |
| CN112601553A (zh) | 2018-06-18 | 2021-04-02 | 拜耳股份有限公司 | 具有可酶切的接头和改善的活性谱的针对cxcr5的结合剂-药物缀合物 |
| CN110835374A (zh) * | 2018-08-19 | 2020-02-25 | 普米斯生物技术(苏州)有限公司 | 抗ccr8×ctla-4双特异性抗体及其应用 |
| US20210393692A1 (en) | 2018-11-13 | 2021-12-23 | Memorial Sloan Kettering Cancer Center | Compositions and methods for adoptive cell therapy for cancer |
| WO2020138489A1 (ja) * | 2018-12-27 | 2020-07-02 | 塩野義製薬株式会社 | 新規抗ｃｃｒ８抗体 |
| CA3160204A1 (en) | 2020-01-06 | 2021-07-15 | Vaccinex, Inc. | Anti-ccr8 antibodies and uses thereof |
| TWI890283B (zh) * | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| US20250019449A1 (en) | 2020-03-05 | 2025-01-16 | Memorial Sloan Kettering Cancer Center | Anti-ccr8 agents |
| AU2021244200A1 (en) | 2020-03-23 | 2022-11-24 | Bristol-Myers Squibb Company | Anti-CCR8 antibodies for treating cancer |
| WO2022004760A1 (ja) | 2020-06-30 | 2022-01-06 | 塩野義製薬株式会社 | 抗ｃｃｒ８抗体と化学療法剤の併用 |
| WO2022003156A1 (en) | 2020-07-02 | 2022-01-06 | Oncurious Nv | Ccr8 non-blocking binders |
| KR102885432B1 (ko) | 2020-07-03 | 2025-11-14 | 난징 이뮤노파지 바이오테크 코., 엘티디. | CCR8 억제제로 Tregs를 표적화하는 방법 및 조성물 |
| WO2022053031A1 (en) | 2020-09-11 | 2022-03-17 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric ccr8 |
| CN118852430A (zh) * | 2023-04-28 | 2024-10-29 | 南京诺艾新生物技术有限公司 | 一种抗趋化因子受体8的抗体及其应用 |
-
2021
- 2021-06-24 TW TW110123093A patent/TW202216771A/zh unknown
- 2021-06-25 CN CN202311684511.5A patent/CN117653725A/zh active Pending
- 2021-06-25 KR KR1020237002375A patent/KR20230028780A/ko active Pending
- 2021-06-25 WO PCT/EP2021/067504 patent/WO2021152186A2/en not_active Ceased
- 2021-06-25 CA CA3188142A patent/CA3188142A1/en active Pending
- 2021-06-25 JP JP2022579794A patent/JP2023531988A/ja active Pending
- 2021-06-25 WO PCT/EP2021/067578 patent/WO2021260208A2/en not_active Ceased
- 2021-06-25 JP JP2022579797A patent/JP2023531990A/ja active Pending
- 2021-06-25 CN CN202180047358.8A patent/CN116234825A/zh active Pending
- 2021-06-25 PE PE2022003003A patent/PE20231200A1/es unknown
- 2021-06-25 US US18/003,118 patent/US20230250178A1/en active Pending
- 2021-06-25 WO PCT/EP2021/067579 patent/WO2021260209A2/en not_active Ceased
- 2021-06-25 MX MX2022015954A patent/MX2022015954A/es unknown
- 2021-06-25 JP JP2022579796A patent/JP2023531989A/ja active Pending
- 2021-06-25 IL IL298896A patent/IL298896A/en unknown
- 2021-06-25 EP EP21736312.6A patent/EP4171602A2/en active Pending
- 2021-06-25 AU AU2021212327A patent/AU2021212327A1/en active Pending
- 2021-06-25 JP JP2022579795A patent/JP2023531705A/ja active Pending
- 2021-06-25 CN CN202180047298.XA patent/CN116096749A/zh active Pending
- 2021-06-25 JP JP2022579798A patent/JP2023531991A/ja active Pending
- 2021-06-25 CN CN202180047296.0A patent/CN116096395A/zh active Pending
- 2021-06-25 US US17/358,841 patent/US11427640B1/en active Active
- 2021-06-25 WO PCT/EP2021/067574 patent/WO2021260206A2/en not_active Ceased
- 2021-06-25 WO PCT/EP2021/067580 patent/WO2021260210A2/en not_active Ceased
- 2021-06-25 IL IL298910A patent/IL298910A/en unknown
- 2021-06-25 EP EP21736311.8A patent/EP4171601A2/en active Pending
- 2021-06-25 CN CN202180047293.7A patent/CN116096748A/zh active Pending
- 2021-06-25 AU AU2021295721A patent/AU2021295721A1/en active Pending
- 2021-06-25 KR KR1020237002373A patent/KR20230028453A/ko active Pending
- 2021-06-25 CN CN202180047299.4A patent/CN116096750A/zh active Pending
- 2021-06-25 MX MX2022015968A patent/MX2022015968A/es unknown
- 2021-06-25 BR BR112022026121A patent/BR112022026121A2/pt unknown
- 2021-06-25 CA CA3188138A patent/CA3188138A1/en active Pending
- 2021-06-25 CA CA3188146A patent/CA3188146A1/en active Pending
- 2021-06-25 EP EP21736310.0A patent/EP4172201A2/en active Pending
- 2021-06-25 EP EP21736313.4A patent/EP4172202A2/en active Pending
- 2021-06-25 EP EP21734019.9A patent/EP4172204A2/en active Pending
-
2022
- 2022-04-22 US US17/727,220 patent/US12065497B2/en active Active
- 2022-12-23 CL CL2022003747A patent/CL2022003747A1/es unknown
- 2022-12-27 JO JOJO/P/2022/0352A patent/JOP20220352A1/ar unknown
-
2024
- 2024-05-16 US US18/666,545 patent/US20240400700A1/en active Pending
- 2024-05-16 US US18/666,512 patent/US20240376218A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023531988A5 (https=) | ||
| JP2023531989A5 (https=) | ||
| JP2023531990A5 (https=) | ||
| JP2023531991A5 (https=) | ||
| JP2023531705A5 (https=) | ||
| CN113316591A (zh) | Cd73抗体及其制备方法和应用 | |
| NO20161389A1 (no) | Antistoffer som binder til human IGF-IR, hybridomcellelinjer og nukleinsyrer, farmasøytisk blanding omfattende samme, anvendelse av samme for fremstilling av farmasøytisk blanding, fremgangsmåte for fremstilling av farmasøytisk preparat, og anvendelser derav | |
| JP2011525355A5 (https=) | ||
| JP2012143232A5 (https=) | ||
| JP2014509187A5 (https=) | ||
| JP2012197278A5 (https=) | ||
| LTC2567976I2 (lt) | Antikūnai prieš CD38 antigeną, skirti išsėtinės mielomos gydymui | |
| IL209576A (en) | Α1-il antibodies and methods of use | |
| WO2008016854A3 (en) | Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity | |
| JP2017513524A5 (https=) | ||
| JP2006502416A5 (https=) | ||
| JP2024511319A5 (https=) | ||
| EA201000490A1 (ru) | Антигенсвязывающие белки, связывающиеся с человеческим белком gm-csf | |
| NO20081987L (no) | Humane, monoklonale antistoffer mot CD70 | |
| JP2006523595A5 (https=) | ||
| NO20090069L (no) | Malrettede forbindelser rettet mot binding til PDGFR-alfa og deres anvendelse | |
| NO20091283L (no) | Humane antistoffer som binder CXCR4 og anvendelser derav | |
| WO2013192550A3 (en) | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof | |
| WO2007041171A3 (en) | Method of identifying membrane lg specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells | |
| MX354243B (es) | Polipeptidos anticuerpos que antagonizan cd40. |